Who are Arsenic Trioxide Injectable Solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ATO, IV Arsenic Trioxide, Ibrutinib combined with As2O3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arsenic-trioxide-injectable-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Arsenic Trioxide Injectable Solution — Competitive Intelligence Brief

Arsenic Trioxide Injectable Solution (Arsenic Trioxide Injectable Solution) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Arsenic compound; differentiation agent and apoptosis inducer. Area: Oncology.

phase 2 Arsenic compound; differentiation agent and apoptosis inducer PML-RARA fusion protein; mitochondrial apoptotic pathway Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Arsenic Trioxide Injectable Solution (Arsenic Trioxide Injectable Solution) — Medsenic. Arsenic trioxide induces differentiation and apoptosis in leukemic cells, particularly in acute promyelocytic leukemia (APL), through multiple pathways including PML-RARA protein degradation and reactive oxygen species generation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Arsenic Trioxide Injectable Solution TARGET	Arsenic Trioxide Injectable Solution	Medsenic	phase 2	Arsenic compound; differentiation agent and apoptosis inducer	PML-RARA fusion protein; mitochondrial apoptotic pathway
ATO	ATO	South China Children's Leukemia Group	marketed	Arsenic compound; differentiation agent	PML-RARA fusion protein; mitochondrial apoptotic pathways
IV Arsenic Trioxide	IV Arsenic Trioxide	SDK Therapeutics, Inc.	phase 3	Arsenic compound; differentiation agent and apoptosis inducer	PML-RARA fusion protein; mitochondrial apoptotic pathway
Ibrutinib combined with As2O3	Ibrutinib combined with As2O3	Peking University People's Hospital	phase 3	BTK inhibitor combined with arsenic compound	BTK (Bruton's tyrosine kinase); As2O3 has multiple targets including PML-RARA fusion protein and mitochondrial pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Arsenic compound; differentiation agent and apoptosis inducer class)

Medsenic · 1 drug in this class
SDK Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arsenic Trioxide Injectable Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/arsenic-trioxide-injectable-solution. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab